Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation ACC 2024

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Presenter: C. Michael Gibson

April 06, 2024

Presentation

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

October 03, 2017

Presentation CHIP Seattle 2017

Yes, the Data Favor Invasive Management and Revascularization for These Patients (with Ischemic CM)

Presenter: Ajay J. Kirtane

August 10, 2017

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation

The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After PCI: The ADAPT-DES Study

Presenter: Sorin Brener

July 05, 2016

Presentation JIM 2016

Medical therapy optimization with new anti-ischemic drugs

Presenter: Giuseppe Musumeci

February 11, 2016

Presentation

Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-Analysis

Presenter: JH. Badhiwala

November 02, 2015

Presentation

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

Presenter: JA. Gutierrez

October 05, 2015

Presentation

Endovascular Therapy for Acute Ischemic Stroke

Presenter: Partha Sardar

June 22, 2015

Presentation

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Presenter: Sripal Bangalore

April 22, 2014

Presentation

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Presenter: A. Stazi

December 09, 2013

Presentation

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presenter: Eli Lev

December 01, 2013

Presentation

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Presenter: Siddharth A. Wayangankar

April 19, 2013

Presentation ACC 2013

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Presenter: Giuseppe Patti

March 08, 2013

Presentation

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Presenter: Deepak L. Bhatt

April 09, 2012

Presentation

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Presenter: 35236|Harvey White

March 16, 2012

Advertisement

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

Yes, the Data Favor Invasive Management and Revascularization for These Patients (with Ischemic CM)

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After PCI: The ADAPT-DES Study

Medical therapy optimization with new anti-ischemic drugs

Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-Analysis

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

Endovascular Therapy for Acute Ischemic Stroke

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Reduced Immediate Ischemic Events with Cangrelor in PCI: Pooled Analysis of the CHAMPION Trials Using the Universal Definition of MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content